Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director · PRESIDENT AND CEO | October 06, 2026 | October 08, 2026 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | May 25, 2021 | May 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 767,780 |
Ending reported balance
After 2026-10-08 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 2 · 2026-10-06 · Sale · Disposed 2,300 · Balance 785,480 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-10-06 · Sale · Disposed 6,000 · Balance 779,480 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-10-06 · Sale · Disposed 9,920 · Balance 769,560 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-10-06 · Sale · Disposed 1,780 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F5: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-10-07 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 7 · 2026-10-07 · Sale · Disposed 8,600 · Balance 779,180 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F6: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-10-07 · Sale · Disposed 10,300 · Balance 768,880 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F7: Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-10-07 · Sale · Disposed 900 · Balance 767,980 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F8: Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-10-07 · Sale · Disposed 200 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F9: Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-10-08 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 12 · 2026-10-08 · Sale · Disposed 4,810 · Balance 782,970 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F10: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 13 · 2026-10-08 · Sale · Disposed 3,090 · Balance 779,880 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F11: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 14 · 2026-10-08 · Sale · Disposed 11,900 · Balance 767,980 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F12: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 15 · 2026-10-08 · Sale · Disposed 200 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 61,552 |
Reported balance
After 2026-10-06 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-10-06 · Exercise / conversion · Disposed 20,000 · Balance 61,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 41,552 |
Reported balance
After 2026-10-07 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-10-07 · Exercise / conversion · Disposed 20,000 · Balance 41,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 21,552 |
Reported balance
After 2026-10-08 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-10-08 · Exercise / conversion · Disposed 20,000 · Balance 21,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F11: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.
QUEST DIAGNOSTICS INC
Report date May 25, 2021 · Filed May 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,260 |
Reported balance
After 2021-05-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-05-25 · Grant · Acquired 1,363 · Balance 6,260 F1: Represents an award of restricted share units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted share units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2021 Filed Mar 2, 2021 01:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 50,000 | $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-002485 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. Read SEC document |
| February 22, 2021 Filed Feb 22, 2021 23:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 39,354 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002056 · edgar.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 22, 2021 Filed Feb 22, 2021 23:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 19,511 | $48.69 | $949,990.59 |
DisclosureSEC source: 0001179110-21-002056 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,160 F1 · shares: The reported disposition of 19,511 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 22, 2021 Filed Feb 22, 2021 23:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 39,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002056 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 22:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 52,368 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001807 · edgar.xml · derivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,368 Underlying: Common Stock · 52,368 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 22:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 90,134 | $0.00 Strike: $49.84 | $0.00 |
DisclosureSEC source: 0001179110-21-001807 · edgar.xml · derivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,134 Underlying: Common Stock · 90,134 shares Expires 2031-02-15 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 14, 2021 Filed Feb 16, 2021 21:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 28,729 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001686 · edgar.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,729 Underlying: Common Stock · 28,729 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 14, 2021 Filed Feb 16, 2021 21:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 14,243 | $49.84 | $709,871.12 |
DisclosureSEC source: 0001179110-21-001686 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,317 F1 · shares: The reported disposition of 14,243 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 14, 2021 Filed Feb 16, 2021 21:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 28,729 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001686 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 00:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 32,795 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001651 · edgar.xml · derivative · entry 6 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,589 Underlying: Common Stock · 32,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 00:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 16,259 | $49.84 | $810,348.56 |
DisclosureSEC source: 0001179110-21-001651 · edgar.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502,831 F2 · shares: The reported disposition of 16,259 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 00:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 32,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001651 · edgar.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 00:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 31,282 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001651 · edgar.xml · derivative · entry 5 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,844 Underlying: Common Stock · 31,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 00:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 15,509 | $50.60 | $784,755.40 |
DisclosureSEC source: 0001179110-21-001651 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,295 F1 · shares: The reported disposition of 15,509 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 00:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 31,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001651 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 501,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 1, 2021 23:55 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 50,000 | $14.66 Strike: $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-001007 · edgar.xml · derivative · entry 4 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 50,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014. Read SEC document |
| February 01, 2021 Filed Feb 1, 2021 23:55 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 5,437 | $48.51 | $263,735.82 |
DisclosureSEC source: 0001179110-21-001007 · edgar.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,522 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $48.31 to $48.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 01, 2021 Filed Feb 1, 2021 23:55 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 44,563 | $47.76 | $2,128,181.82 |
DisclosureSEC source: 0001179110-21-001007 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,959 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $47.31 to $48.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 01, 2021 Filed Feb 1, 2021 23:55 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 50,000 | $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-001007 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 00:57 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011475 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,522 F1 · shares: REPRESENTS A BONA FIDE GIFT TO A CHARITABLE ORGANIZATION Read SEC document |
| November 25, 2020 Filed Nov 25, 2020 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 50,000 | $14.66 Strike: $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-20-011426 · edgar.xml · derivative · entry 4 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 50,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested one-fourth on the first anniversary of the January 6, 2014 grant date and then 1/48 monthly thereafter. Read SEC document |
| November 25, 2020 Filed Nov 25, 2020 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 27,674 | $41.18 | $1,139,642.99 |
DisclosureSEC source: 0001179110-20-011426 · edgar.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,522 F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.81 to $41.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 25, 2020 Filed Nov 25, 2020 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 22,326 | $40.17 | $896,924.72 |
DisclosureSEC source: 0001179110-20-011426 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,196 F1 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.78 to $40.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 25, 2020 Filed Nov 25, 2020 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 50,000 | $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-20-011426 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 20:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009047 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,522 F1 · shares: REPRESENTS A BONA FIDE GIFT TO A CHARITABLE ORGANIZATION Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 1,531 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-20-000123 · wf-form4_159009341983894.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,897 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 01:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 39,354 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002174 · edgar.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,354 Underlying: Common Stock · 39,354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 01:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 19,511 | $21.83 | $425,925.13 |
DisclosureSEC source: 0001179110-20-002174 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,522 F1 · shares: The reported disposition of 19,511 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 01:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 39,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002174 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 28,730 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001748 · edgar.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,458 Underlying: Common Stock · 28,730 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 14,244 | $21.10 | $300,548.40 |
DisclosureSEC source: 0001179110-20-001748 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,679 F1 · shares: The reported disposition of 14,244 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 28,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001748 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 32,795 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001579 · edgar.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,384 Underlying: Common Stock · 32,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 16,259 | $20.00 | $325,180.00 |
DisclosureSEC source: 0001179110-20-001579 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,193 F1 · shares: The reported disposition of 16,259 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 32,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001579 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 22:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 125,126 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001532 · edgar.xml · derivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,126 Underlying: Common Stock · 125,126 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 22:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 266,051 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001179110-20-001532 · edgar.xml · derivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,051 Underlying: Common Stock · 266,051 shares Expires 2030-02-10 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 55,487 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000987 · edgar.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,487 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 19,910 | $19.21 | $382,471.10 |
DisclosureSEC source: 0001179110-20-000987 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,657 F1 · shares: The reported disposition of 19,910 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 55,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000987 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2019 Filed Feb 4, 2020 21:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000982 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,080 F1 · kind: REPRESENTS A BONA FIDE GIFT TO A CHARITABLE ORGANIZATION. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:40 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 1,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000139 · wf-form4_155803923677560.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,366 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 39,354 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002462 · edgar.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,708 Underlying: Common Stock · 39,354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 19,511 | $16.81 | $327,979.91 |
DisclosureSEC source: 0001179110-19-002462 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,580 F1 · shares: The reported disposition of 19,511 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 39,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002462 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 22:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 28,730 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002004 · edgar.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,188 Underlying: Common Stock · 28,730 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 22:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 14,244 | $16.54 | $235,595.76 |
DisclosureSEC source: 0001179110-19-002004 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,737 F1 · shares: The reported disposition of 14,244 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 22:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 28,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002004 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 131,179 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001931 · edgar.xml · derivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,179 Underlying: Common Stock · 131,179 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 250,218 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001179110-19-001931 · edgar.xml · derivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,218 Underlying: Common Stock · 250,218 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.